• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

By: Talis Biomedical Corporation via GlobeNewswire
August 03, 2023 at 08:00 AM EDT

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

The live webcast of the event may be accessed by registering online for dial-in information via the News & Events page of the investor section of Talis Biomedical’s website at investors.talisbio.com. Participants interested in dialing in to the conference call are requested to register a day in advance or at a minimum 15 minutes before the start of the call to obtain a unique pin for the call.

The webcast will be archived and will be available for replay via the News & Events page following the call.

About Talis Biomedical
Talis Biomedical is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. The company plans to develop and commercialize innovative products on its sample-to-answer Talis One® system to enable accurate, low cost, and rapid molecular testing. For more information, visit talisbio.com.

Contact
Media & Investors
Emily Faucette
ir@talisbio.com
415-595-9407


Primary Logo

More News

View More
Datavault: A Speculative AI Play, But Beware of Volatility
Today 16:42 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
Today 14:28 EDT
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
Today 13:44 EDT
Via MarketBeat
Tickers DAL
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Today 12:12 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers ABSI MRK RXRX
Applied Digital’s Shorts Got Squeezed—Now What?
Today 11:16 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers APLD
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap